Abstract
Celiptium (N2-methyl-9-hydroxy-ellipticinium) is an antitumoral agent used to treat bone metastases from breast carcinomas. This new drug appeared to be of great interest because of the absence of hepato-or myelotoxicity. Three different investigators recently mentioned cases of celiptium-induced renal failure. We therefore undertook a study of renal function and morphology in female Wistar rats. Two single i.v. doses (10 or 20 mg/kg) were administered and animals were sacrificed 4, 8, 15, 28 and 60 days after injection. One group of rats received multiple doses, 5 mg/kg/week for 8 weeks. No mortality was observed. With the 10 mg/kg single dose creatinine clearance (Ccr) and urinary enzymes did not change, and tubular lesions were rare. With the 20 mg/kg single dose CCr decreased on day 4 and returned to normal on day 28. Urinary enzyme excretion (AAP, NAG, γGT) increased. Renal lesions were diffuse with tubular necrosis, luminal dilation and later (day 28) interstitial cellular infiltration. These lesions persisted on day 60 and appeared to be irreversible. Ultrastructural studies showed numerous large fat droplets in proximal tubular cells. Glycerol concentrations in renal cortex homogenates were increased while phospholipids are slightly decreased. With 5 mg/kg every week (multiple doses) Ccr decreased and tubular lesions similar to the observed with the 20 mg/kg single dose were seen. Thus celiptium induced dose-dependent nephrotoxicity in rats with prolonged tubular alterations. Since it has been shown that renal tubular cells metabolized celiptium in vitro into electrophilic intermediates, we suggest that free radicals and quinone derivatives may contribute to peroxidation of unsaturated fatty acids and play a role in the nephrotoxicity of the drug.
Similar content being viewed by others
References
Amiel JF, Ben Ayed F, Tursz T, Droz JP (1981) Chimiothérapie des hépatomes par l'acétate d'elliptinium (NMHE). Nouv Presse Med 10: 2218–2124
Auclair C, Hyland K, Paoletti C (1983) Autooxidation of the antitumor drug 9-hydroxyellipticine and its derivatives. J Med Chem 26: 1438–1444
Auclair C, Voisin E, Banoum H, Paoletti C, Bernadou J (1984) Potential antitumor agents: synthesis and biological properties of aliphatic amino acid o-hydroxyellipticinium derivatives. J Med Chem 27: 1161–1166
Bartlett GR (1959) Phosphorus assay in column chromatography. J Biol Chem 234: 466–468
Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911–917
Branfman AR, Bruni RJ, Reinhold VN, Silveira DM, Chadwich M, Yesair DW (1978) Characterization of the metabolites of ellipticine in rat bile. Drug Metab Dispos 6: 542–548
Chadwick M, Silveira DM, Platz BB, Hayes D (1978) Comparative physiological disposition of ellipticine in several animal species after intravenous administration. Drug Metab Dispos 6: 528–541
Chasson AL, Grady HT, Stanley MA (1961) Determination of creatinine by means of automatic chemical analysis. Am J Clin Pathol 35: 83–88
El Mashak EM, Paoletti C, Tocanne JF (1979) Interactions between ellipticine and some derivatives and phospholipids in model membrane. FEBS Lett 107: 155–159
El Mashak EM, Tocanne JF (1980) Interaction between ellipticine and phospholipids. Effects of ellipticine and 9-methoxyellipticine on the phase behaviour of phosphatidylglycerols. Eur J Biochem 105: 593–601
Juret P, Tanguy A, Girard A (1978) L'acétate d'hydroxy-9-methyl-2-ellipticinium. Etude toxicologique et thérapeutique chez 100 cancéreux. Nouv Presse Med 8: 1494–1498
Juret P, Heron JF, Couette JE, Delozier T, Le Talaer JY (1982) Hydroxy-9-methyl-2-ellipticinium for osseous metastases from breast cancer: a 5 years experience. Cancer Treat Rep 66: 1909–1916
Lempereur L, Sauterau AM, Tocanne JF, Laneelle G (1984) Ellipticine derivatives interacting with model membranes influence of quaternization of nitrogen-2. Biochem Pharmacol 33: 2499–2503
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193: 265–275
Luft FC, Patel LV (1978) In: Fillastre JP (ed) Nephrotoxicity — interaction of drugs with membranes systems mitochondria lysosomes. Masson Publishing USA Inc., pp 127–141
Lullmann H, Lullman-Rauch R, Wassermann D (1978) Lipidosis induced by amphiphilic cationic drug. Biochem Pharmacol 27: 1103–1108
Maftouh M, Meunier G, Dugue B, Monsarrat B, Meunier B, Rao R, Paoletti C (1983) Metabolism of the anti-tumor drugs N2-methyl-9-hydroxyellipticinum acetate (NSC 264137) and N2-methyl-9-hydroxyolivecinium acetate in the rat: preliminary identification of biliary 9 (O)-glucuronide and 10 (S)-glutathione conjugates. Xenobiotica 13: 303–310
Maftouh M, Monsarrat B, Rao RC, Meunier B, Paoletti C (1984) Identification of the glucuronide and glutathione conjugates of the antitumor drug N2-methyl-9-hydroxyellipticinium acetate (celiptium) comparative disposition of this drug with its olivacinium isomer in rat bile. Drug Metab Dispos 12: 211–219
Maftouh M, Amiar Y, Picard-Fraire C (1985) Metabolism of the antitumor drug N2-methyl-9-hydroxyellipticinium acetate in isolated rat kidney cells. Biochem Pharmacol 34: 427–428
Montsarrat B, Maftouh M, Meunier G, Dugue B, Bernadou J, Armand JP, Picard-Fraire C, Meunier B, Paoletti C (1983) Human and rat urinary metabolites of the hydroxy methylellipticinium. Identification of cysteine conjugates supporting the “Biooxidative alkylation” hypothesis. Biochem Pharmacol 32: 3887–3890
Paoletti C, Cros S, Dat Xuong N, Lecointe P, Moisand A (1979) Comparative cytotoxic and antitumoral effects of ellipticine derivatives on mouse L 1210 leukemia. Chem Biol Interact 25:45–58
Paoletti C, Lepecq JB, Dat Xuong N, Juret P, Garnier H, Amiel JL, Rouesse J (1980) Antitumor activity, pharmacology, and toxicity of ellipticines, ellipticinium and 9-hydroxy-derivatives: preliminary clinical trials of 2-methyl-9-hydroxy-ellipticinium (NSC-264-137). Recent Res Cancer Res 74: 107–123
Pratviel G, Bernadou J, Ha T, Meunier G, Cros S, Meunier B, Gillet B, Guittet E (1986) Ribose as the acetate in ribonucleosides. Biological activities of the resulting adducts. J Med Chem 29: 1350–1355
Rouesse J, Tursz T, Lechevalier T, Huertas D, Amiel JL, Brule G, Callet B, Droz JP, Voisin PM, Sancho-Garnier H, Le Pecq JB, Paoletti C (1981) Intérêt de la 2-N-methyl-9-hydroxy-ellipticine (NSC 264-137) dans le traitement des cancers métastasés. Nouv Presse Med 10: 1997–1999
Ryckelynck JP, Heron JF, Juret P, Schneider P, Herlin P, De Ranieri E, Hardouin A, Peny J, Le Talaer JY (1984) Renal toxicity of 9-hydroxy-2-methyl-ellipticinium. Nephrologie 5: 59–63
Terce F, Tocanne JF, Laneelle G (1982) Interactions of ellipticine with model or natural membranes. A spectrophotometric study. Eur J Biochem 125: 203–207
Terce F, Tocanne JF, Laneelle G (1983) Ellipticine induced alteration of model and natural membranes. Biochem Pharmacol 32: 2189–2194
Van Bac N, Moisand CH, Gouyette A, Muzard G, Datxuong N, Le Pecq JB, Paoletti C (1980) Metabolism and disposition studies of 9-hydroxyellipticine and 2-methyl-9-hydroxyellipticinium acetate in animals. Cancer Treat Rep 64: 879–887
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Raguenez-Viotte, G., Dadoun, C., Buchet, P. et al. Renal toxicity of the antitumor drug N2-methyl-9-hydroxyellipticinium acetate in the wistar rat. Arch Toxicol 61, 292–297 (1988). https://doi.org/10.1007/BF00364852
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00364852